Webinar

With its large aging population, Japan is one of the world’s largest markets for health care products. Any pharmaceutical or medical device sold in Japan must be approved by the PMDA, a Japanese national regulatory agency similar to the US FDA. We will discuss foreign entry into this market in Japan and practical considerations for dealing with the PMDA with Ariel Weber, who served as a full-time staff member for three years at the PMDA.

Registration deadline: 16/12/2019

When do I have to pay Consumption Tax when I do business with Japan?

How will Japan use its leadership in bioscience and biotech to make its economy sustainable?

Japan is quietly becoming a world leader in nanotechnology: what are the recent trends of this sector?

What are the business opportunities in Japan’s public healthcare and what you need to do to become a supplier?

What are the EPA agri-food preferences offered within Tariff Rate Quotas?

The EPA is offering tariff concessions within 25 agri-food related Tariff Rate Quotas (TRQs).  Knowledge about the functioning of these TRQs increases related export potentials. 

As a professional service provider, where can I find the information to do business in Japan? Is it necessary to have my professional qualification recognised?

What to know before starting trade exchanges with Japan?

What are important differences between the appeal proceedings at the EPO and JPO?

While efforts have been made to harmonize the process of IP prosecution around the world, important differences remain that must be understood in order to achieve efficient prosecution in each jurisdiction. One such example is appeal proceedings before the EPO and JPO.

Do you want strategic and pragmatic advice on how to deal with Japanese post-M&A challenges?